169 related articles for article (PubMed ID: 36083490)
1. Effect of treatment with Fufang Huangqi decoction on dose reductions and discontinuation of pyridostigmine bromide tablets, prednisone, and tacrolimus in patients with type I or II myasthenia gravis.
Caifeng S; Jingsheng Z; Yi L; Xueshi H; Zhanyou W; Haiou P; Wenjun Q
J Tradit Chin Med; 2022 Oct; 42(5):810-817. PubMed ID: 36083490
[TBL] [Abstract][Full Text] [Related]
2. Tacrolimus Improves Symptoms of Children With Myasthenia Gravis Refractory to Prednisone.
Liu C; Gui M; Cao Y; Lin J; Li Y; Ji S; Bu B
Pediatr Neurol; 2017 Dec; 77():42-47. PubMed ID: 29074055
[TBL] [Abstract][Full Text] [Related]
3. Effect of Fufang Huangqi Decoction on the Gut Microbiota in Patients With Class I or II Myasthenia Gravis.
Chen Y; Lin Y; Shan C; Li Z; Xiao B; He R; Huang X; Wang Z; Zhang J; Qiao W
Front Neurol; 2022; 13():785040. PubMed ID: 35370890
[TBL] [Abstract][Full Text] [Related]
4. Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment.
Kupersmith MJ; Ying G
Br J Ophthalmol; 2005 Oct; 89(10):1330-4. PubMed ID: 16170126
[TBL] [Abstract][Full Text] [Related]
5. The effect of use of pyridostigmine and requirement of vecuronium in patients with myasthenia gravis.
Tripathi M; Kaushik S; Dubey P
J Postgrad Med; 2003; 49(4):311-4; discussion 314-5. PubMed ID: 14699228
[TBL] [Abstract][Full Text] [Related]
6. The effectiveness and side effects of pyridostigmine in the treatment of myasthenia gravis: a cross-sectional study.
Remijn-Nelissen L; Verschuuren JJGM; Tannemaat MR
Neuromuscul Disord; 2022 Oct; 32(10):790-799. PubMed ID: 36184373
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic efficacy and immunoregulatory effect of Qiangji Jianli Capsule for patients with myasthenia gravis: Study protocol for a series of randomized, controlled N-of-1 trials.
Weng S; Fan Z; Qiu G; Liu F; Huang L; Li J; Jiang X; Song Z; Gao Y; Zhong Z; He L; Kang L; Wu Y; Chen B; Jiang Q
Medicine (Baltimore); 2020 Dec; 99(51):e23679. PubMed ID: 33371107
[TBL] [Abstract][Full Text] [Related]
8. The effect of prednisone on the progression from ocular to generalized myasthenia gravis.
Monsul NT; Patwa HS; Knorr AM; Lesser RL; Goldstein JM
J Neurol Sci; 2004 Feb; 217(2):131-3. PubMed ID: 14706214
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of tacrolimus in Osserman grade III and Osserman grade IV Myasthenia Gravis.
Zhao LN; Liang Y; Fang XJ; Liu XM; Jiang QL; Wang SS; She SF; Cao M
Clin Neurol Neurosurg; 2018 Oct; 173():70-76. PubMed ID: 30092406
[TBL] [Abstract][Full Text] [Related]
10. [Analysis for the effect of different regimens on ocular myasthenia gravis in children].
Liu C; Wang X; Xie L; Peng J; Wu L; Zheng X
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Nov; 42(11):1275-1279. PubMed ID: 29187654
[TBL] [Abstract][Full Text] [Related]
11. Depression: A Contributing Factor to the Clinical Course in Myasthenia Gravis Patients.
Mihalache OA; Vilciu C; Petrescu DM; Petrescu C; Manea MC; Ciobanu AM; Ciobanu CA; Popa-Velea O; Riga S
Medicina (Kaunas); 2023 Dec; 60(1):. PubMed ID: 38256317
[No Abstract] [Full Text] [Related]
12. Celebrating the 70 years of pyridostigmine on therapy of Myasthenia Gravis: historical aspects of the preliminary trials.
Lorenzoni PJ; Kay CSK; Ducci RD; Fustes OJH; Werneck LC; Scola RH
Arq Neuropsiquiatr; 2020 Mar; 78(3):179-181. PubMed ID: 32215460
[TBL] [Abstract][Full Text] [Related]
13. Factors associated with insensitivity to pyridostigmine therapy in Thai patients with ocular myasthenia gravis.
Chirapapaisan N; Tanormrod S; Chuenkongkaew W
Asian Pac J Allergy Immunol; 2007 Mar; 25(1):13-6. PubMed ID: 17891917
[TBL] [Abstract][Full Text] [Related]
14. Successful desensitization protocol for pyridostigmine in a 12 year old patient with myasthenia gravis.
Kaplan F; Topal E
Turk J Pediatr; 2023; 65(2):326-329. PubMed ID: 37114698
[TBL] [Abstract][Full Text] [Related]
15. Remission and relapses of myasthenia gravis on long-term tacrolimus: a retrospective cross-sectional study of a Chinese cohort.
Bi Z; Cao Y; Liu C; Gui M; Lin J; Zhang Q; Li Y; Ji S; Bu B
Ther Adv Chronic Dis; 2022; 13():20406223221122538. PubMed ID: 36093262
[TBL] [Abstract][Full Text] [Related]
16. Development of generalized disease at 2 years in patients with ocular myasthenia gravis.
Kupersmith MJ; Latkany R; Homel P
Arch Neurol; 2003 Feb; 60(2):243-8. PubMed ID: 12580710
[TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy and safety of tacrolimus in young children with myasthenia gravis.
Zhang Y; Zhang M; Zhang L; Zhou S; Li W
J Clin Neurosci; 2023 Oct; 116():93-98. PubMed ID: 37669613
[TBL] [Abstract][Full Text] [Related]
18. The natural history and ophthalmic involvement in childhood myasthenia gravis at the hospital for sick children.
Mullaney P; Vajsar J; Smith R; Buncic JR
Ophthalmology; 2000 Mar; 107(3):504-10. PubMed ID: 10711889
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness and safety of intravenous methylprednisolone and tacrolimus monotherapy in ocular myasthenia gravis with unsatisfactory prednisone responses: a retrospective study.
Zhang KY; Duan WW; Luo YB; Li Y; Hu J; Yang H
Orphanet J Rare Dis; 2024 Jan; 19(1):19. PubMed ID: 38243274
[TBL] [Abstract][Full Text] [Related]
20. Does early treatment of ocular myasthenia gravis with prednisone reduce progression to generalized disease?
Kupersmith MJ
J Neurol Sci; 2004 Feb; 217(2):123-4. PubMed ID: 14706212
[No Abstract] [Full Text] [Related]
[Next] [New Search]
